Boston Scientific Corporation (NYSE:BSX) has entered into a definitive agreement to acquire Intera Oncology Inc. for approximately $180 million on November 25, 2024. The purchase price consists of an upfront cash payment of approximately $175 million. The Intera business will be integrated into Boston Scientific's Peripheral Interventions division.
Boston Scientific expects to complete the transaction in the first half of 2025, subject to closing conditions. As per updated filing, The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions.
